Open Access Open Access  Restricted Access Subscription or Fee Access

A Review on Effect of Fluoxetine on Human Brain

Shishir Tyagi, Akshita Vishnoi, Raxit Tyagi, Surya Prakash D.V

Abstract


Fluoxetine is a frequently prescribed antidepressant drug that primarily affects the neurotransmitter system of the human brain. Fluoxetine affects the brain by preventing serotonin from being reabsorbed, which raises the concentration of serotonin in the synaptic cleft. In numerous neuronal circuits across the brain, serotonin, a neurotransmitter linked to mood regulation and emotional stability, is essential. By inhibiting the serotonin transporter, fluoxetine increases serotonin transfer and promotes neurotransmission in these circuits. When fluoxetine is used, serotonin synaptic availability increases, which affects cognition, emotions, and mood. By modifying the serotonergic pathways, it is thought that fluoxetine can reduce the signs and symptoms of anxiety and depression while also promoting a more stable and balanced mood

Keywords


Fluoxetine, brain, inhibitor, neuron, health

Full Text:

PDF

References


Shah AJ, Veledar E, Hong Y, Bremner JD, Vaccarino V. Depression and history of attempted suicide as risk factors for heart disease mortality in young individuals. Archives of general psychiatry. 2011 Nov 7;68(11):1135–42

Adjei K, Adunlin G, Ali AA. Impact of Sertraline, Fluoxetine, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder. In Healthcare 2023 Mar 3 (Vol. 11, No. 5, p. 740). MDPI.

Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). The Journal of clinical psychiatry. 2015 Feb 25;76(2):5356.

Thaler K, Gartlehner G, Hansen RA, Morgan LC, Lux LJ, Van Noord M, Mager U, Gaynes BN, Thieda P, Strobelberger M, Lloyd S. The comparative efficacy of second-generation antidepressants for the accompanying symptoms of depression: A systematic review. European

Psychiatry. 2011 Mar;26(S2):697–.

Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?. International clinical psychopharmacology. 2014 Jul;29(4):185.

Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurology International. 2021 Aug 5;13(3):387–401.

Lam RW. Antidepressants and QTc prolongation. Journal of Psychiatry and Neuroscience. 2013 Mar 1;38(2):E5–6.

Noordam R, Aarts N, Verhamme KM, Sturkenboom MC, Stricker BH, Visser LE. Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. European journal of clinical pharmacology. 2015 Mar;71:369–75.

Haro JM, Lamy FX, Jönsson B, Knapp M, Brignone M, Caillou H, Chalem Y, Hammer-Helmich L, Rive B, Saragoussi D. Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study. BMC psychiatry. 2018

Dec;18:1–1.

Viertiö S, Kiviruusu O, Piirtola M, Kaprio J, Korhonen T, Marttunen M, Suvisaari J. Factors contributing to psychological distress in the working population, with a special reference to gender difference. BMC public health. 2021 Dec;21:1–7.

Mauramo E, Lahti J, Lallukka T, Lahelma E, Pietiläinen O, Rahkonen O. Changes in common mental disorders and diagnosis-specific sickness absence: a register-linkage follow-up study among Finnish municipal employees. Occupational and Environmental Medicine. 2019 Apr 1;76(4):230–5.

Kalra S, Jena BN, Yeravdekar R. Emotional and psychological needs of people with diabetes. Indian journal of endocrinology and metabolism. 2018 Sep;22(5):696.

Kang YK, Guo WJ, Xu H, Chen YH, Li XJ, Tan ZP, Li N, Gesang ZR, Wang YM, Liu CB, Luo Y. The 6-item Kessler psychological distress scale to survey serious mental illness among Chinese undergraduates: Psychometric properties and prevalence estimate. Comprehensive psychiatry. 2015 Nov 1;63:105–12.

Shah D, Vaidya V, Patel A, Borovicka M, Goodman MH. Assessment of health-related quality of life, mental health status and psychological distress based onthe type of pharmacotherapy used among patients with depression. Quality of Life Research. 2017 Apr;26:969–80.

Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. Psychological bulletin. 2017 Aug;143(8):783.

Albert PR. Why is depression more prevalent in women?. Journal of Psychiatry and Neuroscience. 2015 Jul 1;40(4):219–21.

Lee J. Mental health effects of school closures during COVID-19. The Lancet Child & Adolescent Health. 2020 Jun 1;4(6):421.

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018 Apr 7;391(10128):1357–66




DOI: https://doi.org/10.37591/(rrjobt).v13i2.1451

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Biotechnology